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Abstract
Background: The purpose of this retrospective study was to determine the prognosis of non-serous epithelial
ovarian cancer (EOC) patients with exclusively retroperitoneal lymph node (LN) metastases, and to compare the
prognosis of these women to that of patients who had abdominal peritoneal involvement.
Methods: A multicenter, retrospective department database review was performed to identify patients with stage
III non-serous EOC at 7 gynecologic oncology centers in Turkey. Demographic, clinicopathological and survival data
were collected. The patients were divided into three groups based on the initial sites of disease: 1) the retroperitoneal
(RP) group included patients who had positive pelvic and /or para-aortic LNs only. 2) The intraperitoneal (IP) group
included patients with > 2 cm IP dissemination outside of the pelvis. These patients all had a negative LN status, 3) The
IP / RP group included patients with > 2 cm IP dissemination outside of the pelvis as well as positive LN status. Survival
data were compared with regard to the groups.
Results: We identified 179 women with stage III non-serous EOC who were treated at 7 participating centers during
the study period. The median age of the patients was 53 years, and the median duration of follow-up was 39 months.
There were 35 (19.6%) patients in the RP group, 72 (40.2%) in the IP group and 72 (40.2%) in the IP/RP group. The 5-
year disease-free survival (DFS) rates for the RP, the IP, and IP/RP groups were 66.4%, 37.6%, and 25.5%, respectively
(p = 0.002). The 5-year overall survival (OS) rate for the RP group was significantly longer when compared to those of
the IP, and the IP/RP groups (74.4% vs. 54%, and 36%, respectively; p = 0.011). However, we were not able to define “RP
only disease” as an independent prognostic factor for increased DFS or OS.
Conclusions: Primary non-serous EOC patients with node-positive-only disease seem to have better survival when
compared to those with extra-pelvic peritoneal involvement.
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Background
Epithelial ovarian cancer (EOC) is known to metastasize
to the retroperitoneal lymph nodes (LNs) but only about
9% spread to the LNs in the absence of or with minimal
spread to the peritoneal cavity [1, 2]. Previous studies indi-
cate that these cases have a better prognosis than that of
tumors with abdominal peritoneal involvement [3–10].
Although informative, previous studies were limited by
heterogeneous patient samples with regard to the histo-
logical subtype [3–5, 7, 9] or residual disease (RD) status
[3, 4, 6–8, 10]. Additionally, frequent use of cyclophospha-
mide in first-line chemotherapy regimens might have
acted as a confounding factor in earlier studies [3, 4, 6, 7].
Today, it is well-known that ovarian cancer is not a
single disease but rather a group of diseases - each with
different morphology and biologic behavior [11]. At least
five main types are currently distinguished: high-grade
serous carcinoma (HGSC [70%]), endometrioid carcin-
oma (10%), clear-cell carcinoma (10%), mucinous carcin-
oma (3%), and low-grade serous carcinoma (LGSC [<
5%]) [12]. It is well-known that tumor histology influ-
ences the incidence of nodal disease [13, 14], chemo sen-
sitivity [15], and prognosis [16]. Thus, distinct
histopathological features might characterize tumor cells
metastasizing through the lymphatic route compared to
the trans-coelomic route.
However, previous studies which have investigated the
subgroup of patients with exclusively retroperitoneal LN
metastases generally analyzed all histologic types simul-
taneously [3, 4, 7, 9, 10] and included mostly patients
with serous EOC [3–10]. Under the current perspective
that the different histological subtypes in ovarian cancer
probably represent different disease entities [17], we
wondered whether the favorable prognosis for serous
EOC characterized by node-positive-only disease [8] is
also valid for patients with non-serous EOC such as
endometrioid, clear-cell and mucinous subtypes. Attrib-
uted to the rarity of the condition, we designed this mul-
ticenter, collaborative study in order to shed some light
on this issue. The purpose of this retrospective study
was to determine the prognosis of non-serous EOC pa-
tients with exclusively retroperitoneal LN metastases,
and to compare the prognoses of these women to those
of patients who had abdominal peritoneal involvement.
Methods
Study design and eligibility
Medical records of women who underwent primary sur-
gical treatment for EOC between January 2007 and De-
cember 2016 at seven gynecologic oncology centers
from Turkey were retrospectively reviewed. The study
protocol was approved by the Local Institutional Review
Board (Zekai Tahir Burak Women’s Health Training and
Research Hospital, Faculty of Medicine, University of
Health Sciences, Ankara, Turkey, IRB Approval Num-
ber:10, Date: Nov 2nd, 2016). All patients provided an
informed consent regarding research use of their med-
ical information at admission.
The study population included women who had non-
serous EOC (i.e., endometrioid, clear-cell, mucinous, and
mixed subtypes) with histopathologically proven Stage
III [18] disease. Women were included if they underwent
primary surgical treatment including total hysterectomy
plus bilateral salpingo-oopherectomy, with bilateral pel-
vic and para-aortic lymphadenectomy and other surgical
procedures resulting in optimal debulking. All patients
had to have RD of 1 cm or less in order to be eligible.
Patients who were cytoreduced to greater than 1 cm of
RD were excluded. Since this study focused only on
women having non-serous EOC; women with HGSC,
those with LGSC were excluded as well as patients hav-
ing no lymphadenectomy. We also excluded patients
who received neoadjuvant chemotherapy, women with
synchronous malignancies, and those with incomplete
medical records.
Clinical information
Patient data were extracted from 7 institutions with
maintained EOC databases. With the eligible cases, the
following information was abstracted from medical re-
cords: demographic characteristics, preoperative serum
cancer antigen 125 (CA 125) level, date and type of sur-
gical procedure, presence or absence of ascites, the sta-
tus of peritoneal cytology examination (negative,
positive, or not performed), size of the primary tumor,
bilaterality, size of residual tumor after surgery, stage of
disease, time to recurrence, site of recurrence, length of
follow-up and survival. Tumor characteristics were ab-
stracted from original pathology reports. Data were col-
lected from centers with an online standardized form.
Data on the extent of surgery included number of total
LNs harvested, number of pelvic LNs removed, and
number of para-aortic LNs removed and number of
metastatic LNs. All operations were performed by gyne-
cologic oncologists with intent to achieve optimal cytor-
eduction. Lymphadenectomy was performed after
completion of other cytoreductive procedures. The deci-
sion to perform lymphadenectomy was determined by
the surgeon’s discretion.
All surgical specimens were examined and interpreted
by gynecologic pathologists. Non-serous EOC was diag-
nosed after examination of permanent sections. Archi-
tectural grading was defined by standard International
Federation of Gynecology and Obstetrics (FIGO) criteria.
All tumors were staged according to the 2014 FIGO sta-
ging system [18]. In patients treated before 2014, stage
was determined retrospectively on the basis of surgical
and pathologic assessment.
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The current study investigated cases with mixed non-
serous histologies (including mucinous, clear-cell, endo-
metrioid, and transitional cell types) as a separate group,
and did not assign mixed tumors according to the dom-
inant component. Mixed tumors were diagnosed accord-
ing to the World Health Organization (WHO)
definition; in that more than one cell type was present,
and the minority component accounted for at least 10%
of the tumor. Mixed tumors containing serous compo-
nent were excluded. For the purposes of this study, only
pure tumors were classified as endometrioid, clear-cell
or mucinous whereas tumors having more than one-cell
type were classified as mixed.
The treatment policies were decided by the attending
physician or by the multidisciplinary tumor board at
each participating institution. Adjuvant chemotherapy
was administered to all patients. The standard primary
chemotherapy regimen included paclitaxel 175 mg/m2
plus carboplatin dosed at an area under curve of 5 or 6
every 21 days for 6 cycles.
Patients returned for follow-up evaluation every
3 months for the first 2 years, every 6 months for the next
3 years, and annually thereafter. Computed tomography
or magnetic resonance imaging was performed annually.
Survival data were last calculated on 31st December 2016.
The survival status of the patients was determined as alive
or dead at the time of the last follow-up. For all study sub-
jects with a recorded death, this was confirmed by per-
forming a social security death index search.
Definitons
The patients were divided into three groups based on the
initial sites of disease described by Rungruang et al. [9]: i)
the retroperitoneal (RP) group included patients who had
positive pelvic and/or para-aortic LNs only. By definition,
these patients had < 2 cm intraperitoneal (IP) disease out-
side of the pelvis, ii) the intraperitoneal (IP) group included
patients with > 2 cm IP dissemination outside of the pelvis.
These patients all had a negative LN status, iii) the IP / RP
group included patients with > 2 cm IP dissemination out-
side of the pelvis as well as positive LN status.
Optimal cytoreduction was defined as less than or
equal to 1 cm maximal diameter of the largest residual
tumor nodule at the completion of the primary oper-
ation. Maximal cytoreduction was defined as no macro-
scopic residual disease at the end of the primary
operation. Suboptimal debulking was defined as > 1 cm
of residual disease. Lymphadenectomy was defined as
the performance of pelvic and para-aortic LN dissection
at the same time. We defined pelvic lymphadenectomy
as removal of the lymphatic tissue in the external, in-
ternal and common iliac and obturator regions. Para-
aortic lymphadenectomy was defined as removal of the
lymphatic tissue over the inferior vena cava and aorta
beginning at the level of aortic bifurcation up to the left
renal vessels.
Disease-free survival (DFS) was defined as the time, in
months, from the date of primary surgery until the date
of documented recurrence on the basis of clinical exam-
ination or radiologic imaging; or death from any cause,
whichever occurred first, or the date of last contact for
patients remaining alive without recurrent disease. Pa-
tients who had no active ovarian cancer at the last con-
tact were censored in the DFS analysis. Overall survival
(OS) was calculated as the time period, in months, be-
tween the date of primary surgery to the date of death
or the last contact. Surviving patients were censored at
their last known follow-up.
Statistical analysis
Statistical analyses were performed using the statistical
software package SPSS version 23.0 (SPSS, Inc., Chicago,
IL). The data were expressed as median and range for
continuous variables. The continuous variables such as
age and tumor size have been divided into categories ac-
cording to the median values. Binary variables were re-
ported as counts and percentages.
One-way ANOVA was used to compare normally dis-
tributed variables among the groups (RP, IP, IP/RP).
Levene test was used to assess the homogenity of vari-
ances. An overall p-value of less than 0.05 was consid-
ered to show a statistically significant result. When an
overall significance was observed, pairwise post-hoc tests
were performed using Tukey’s test. Kruskal-Wallis tests
were conducted to compare the variables which were
not distributed normally among the groups (RP, IP, IP/
RP). The Mann-Whitney U test was performed to test
the significance of pairwise differences using Bonferroni
correction to adjust for multiple comparisons.
Survival curves were generated using the Kaplan-
Meier method, and the differences between survival
curves were calculated using the log-rank test. In order
to evaluate the prognostic factors for DFS and OS, a uni-
variate Cox-regression model was used. Any p-value of
less than 0.05 in the univariate analysis was included
into the multivariate analysis. A p-value < 0.05 was con-
sidered to indicate statistical significance.
Results
During the study period, a total of 416 non-serous EOC
were treated at seven participating centers. Of those, 276
women had histopathologically proven Stage III disease.
Seventy two women who had suboptimal debulking and/
or no lymphadenectomy were excluded from the study.
We excluded 15 patients who received neoadjuvant
chemotherapy, two with synchronous malignancies, and
eight women with incomplete medical records. Therefore,
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the present analysis addresses the remaining 179 women
with Stage III non-serous EOC.
The median age of the patients was 53 (range, 18-78)
years, and the median duration of follow-up was 39
(range, 1-120) months. There were 35 (19.6%) patients in
the RP group, 72 (40.2%) in the IP group and 72 (40.2%)
in the IP/RP group. Table 1 demonstrates the clinical and
pathological characteristics of women with regard to the
route of spread. The groups were balanced for prognostic
factors including age, menopausal status, histopathological
subtype, FIGO grade, tumor size, and the number of LNs
retrieved. Patients in the IP/RP group were more likely to
have high baseline serum CA 125 levels (p = 0.001), ascites
(p = 0.001), and bilateral tumors (p = 0.002) when com-
pared to women in the RP and the IP groups. Women in
the IP and the IP/RP groups were more likely to have
positive peritoneal cytology (p < 0.001) when compared to
women in the RP group (Table 1).
The median DFS varied significantly among the
groups. The median DFS for the RP group “has not been
reached yet” compared to 36 months of median DFS in
the IP group (%95 confidence interval [CI] 18.5-53.5
standard error [SE]: 8.92), and 20 months of median
DFS in the IP/RP group (%95 CI 14.-26, SE: 3.06), p =
0.002 (Fig. 1). The 5-year DFS rates for the RP, the IP,
and IP/RP groups were 66.4, 37.6 and 25.5%, respectively
(p = 0.002). When DFS analyses were conducted by
comparing the groups two at a time, the DFS rate for
the RP group was significantly higher than that of the IP
group (p = 0.011) as well as the IP/RP group (p = 0.001).
However, there was no statistically significant difference
in terms of DFS when the IP group was compared to the
IP/RP group (p = 0.18).
The median OS of the RP group has not been reached
yet. This figure was significantly longer than those of the
IP (65 months, %95 CI 48.4-81.53, SE: 8.43), and the IP/
RP (43 months, %95 CI 31.9-54, SE: 5.65) groups, p =
0.011 (Fig. 2). The 5-year OS rate for the RP group was
significantly higher when compared to those of the IP,
and the IP/RP groups (74.4% vs. 54%, and 36%, respect-
ively; p = 0.011). When OS analyses were conducted by
comparing the groups two at a time, the OS rate for the
RP group was significantly higher than that of the IP
group (p = 0.043) as well as the IP/RP group (p = 0.004).
However, there was no statistically significant difference
in terms of OS when the IP group was compared to the
IP/RP group (p = 0.18).
For the entire cohort, univariate analysis revealed age >
53 years (p = 0.025), postmenopausal status (p = 0.03),
IP/RP disease (p = 0.002), bilaterality (p = 0.01), omental
involvement (p < 0.001), grade 3 disease (p < 0.001) and
optimal debulking (p < 0.001) as significant factors for
decreased DFS (Table 2). According to the multivariate
analysis, grade 3 disease (Hazard ratio [HR] 2.3, 95%[CI]
1.42-3.92; p = 0.001), and optimal debulking (HR 5.3,
95% CI 2.37-12.14; p < 0.001), remained as independent
prognostic factors for decreased DFS (Table 2).
For the entire cohort, univariate analysis revealed age >
53 years (p = 0.004), postmenopausal status (p = 0.001),
IP/RP disease (p = 0.011), omental involvement (p =
0.001), grade 3 disease (p = 0.003) and optimal debulking
(p < 0.001) as significant factors for decreased OS
(Table 3). Multivariate analysis demonstrated grade 3
disease (HR 1.90; 95% CI, 1.07-3.42, p = 0.028) and opti-
mal debulking (HR 5.50; 95% CI, 1.96-15.62, p = 0.001)
as independent predictors of decreased OS (Table 3).
At the time of reporting, of 179 women with non-
serous EOC, 99 (55.3%) were alive and 80 (44.7%) were
dead. Since the number of women with node-positive-
only disease was limited for each histotype group (i.e.,
endometrioid [n = 12], clear cell [n = 10], mucinous [n =
10], and mixed [n = 3]), we were unable to perform sub-
group analyses for each histologic group.
Discussion
To the best of our knowledge, this is the first study to
investigate the prognostic impact of route of spread in
advanced non-serous EOC with specific regard to the
tumor histotype. Our results indicate a significant im-
provement in DFS and OS for RP only involvement
compared to IP only tumor or a combination of IP and
RP disease in a cohort of 179 women with non-serous
EOC.
However, we should underline some limitations of the
current study. First, the present study has potential limi-
tations of selection bias and a relatively small number of
patients in each histologic subgroup, which may be in-
herent in any retrospective study. Second, our study was
restricted by the lack of central pathology review. How-
ever, given the low prevalence of node-positive-only dis-
ease in EOC, the study design used here was necessary
to achieve a satisfactory sample size. Despite above limi-
tations, our study contributes to the limited body of
knowledge on this topic.
Accumulating evidences in the literature indicate that
patients with exclusively LN metastases have an im-
proved outcome than that of tumor with abdominal
peritoneal involvement [3–10]. In some of the previous
studies [5, 6, 10], the number of patients with non-
serous EOC was not mentioned and no information has
been given with regard to the histotype. However, in the
study by Onda et al. [3], there were 48 patients with ser-
ous EOC whereas 55 patients had non-serous histology.
Kanazawa et al. [4] reported on 54 patients with serous
and 57 women with non-serous EOC. Baek et al. [7] in-
cluded 197 serous and 65 non-serous EOC patients and
reported on 41 patients with node-positive-only disease.
In the largest study reported to date, Rungruang et al.
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[9] reported on 290 serous and 127 non-serous EOC pa-
tients. All of the above-mentioned studies were
heterogenous with regard to the histotype.
The current study included 179 women with non-
serous histotype with 35 patients with exclusively LN in-
volvement. Our study represents the largest cohort of
patients with non-serous EOC with exclusively LN in-
volvement (Table 2). Compared with previous studies
[3–7, 9, 10], our cohort seems to be more homogenous
with all patients having non-serous histotype, and all pa-
tients having undergone optimal cytoreduction as well
as LND. Additionally, all patients were treated with the
Table 1 Clinicopathologic characteristics of the patients according to the route of disease spread (n = 179)
RP Group
(n = 35)
IP Group
(n = 72)
IP/RP Group
(n = 72)
p
Age (median, range) 50 (18-74) 54 (28-78) 54 (27-77) 0.18
Menopausal Status (n, %) 0.23
Premenopausal 18 (51.4) 25 (34.7) 27 (37.5)
Postmenopausal 17 (48.6) 47 (65.3) 45 (62.5)
Histology (n, %) 0.42
Endometrioid 12 (34.3) 23 (31.9) 17 (23.6)
Clear-cell 10 (28.6) 15 (20.8) 23 (31.9)
Mucinous 10 (28.6) 24 (33.3) 13 (18.1)
Mixed 3 (8.6) 10 (13.9) 19 (26.4)
Gradea (n, %) 0.078
1 5 (20) 8 (14) 6 (12.2)
2 9 (36) 26 (45.6) 10 (20.4)
3 11 (44) 23(40.4) 3 (67.3)
Baseline Serum CA 125
(u/mL) (median, range)
118 (10-3305) 200 (11-9523) 400 (10-11,779) 0.001b
Tumor size (cm)
(median, range)
12 (4-30) 10 (3-39) 10 (3-40) 0.27
Ascites (n, %) 0.001b
Yes 12 (34.3) 37 (51.4) 51 (70.8)
No 23 (65.7) 35 (48.6) 21 (29.2)
Peritoneal cytology (n, %) < 0.001b
Positive 12 (34.3) 53 (73.6) 53 (73.6)
Negative 23 (65.7) 19 (26.4) 19 (26.4)
Bilaterality 0.002b
Yes 10 (28.6) 28 (38.9) 44 (61.1)
No 25 (71.4) 44 (61.1) 28 (38.9)
Total number of
LNs removed
(median, range)
43 (15-105) 37.5 (15-93) 40 (15-103) 0.71
Number of pelvic
LNs removed
(median, range)
25 (10-93) 28.5 (10-75) 28.5 (10-71) 0.97
Number of para-aortic
LNs removed
(median, range)
11 (5-46) 8.5 (5-45) 10 (5-54) 0.57
CRS 0.009
Optimal 17 (48.6) 17(30.9) 17(30.9)
Maximal 18 (51.4) 55(69.1) 55(69.1)
Abbreviations: RP retroperitoneal only disease, IP intraperitoneal only disease, IP/RP combination of intraperitoneal and retroperitoneal disease, n number, LN
lymph node, CRS cytoreductive surgery
aPatients with clear-cell histology were excluded from the statistical analysis
bp values in bold characteristics refer to statistical significance
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standard paclitaxel/carboplatin regimen postoperatively.
These factors seem to reduce the possibility of con-
founding, and enhance the reliability of the prognostic
effects those have been estimated.
The primary routes of ovarian cancer metastasis in-
clude intra-peritoneal implantation of exfoliated cells at
distinct sites and spreading through the retroperitoneal
lymphatic channels [19]. The presence of tumor
spreading mainly through lymphatic channels without
intra-peritoneal dissemination suggests that such tu-
mors might be associated with a favorable biologic be-
havior [10]. One plausible explanation for the favorable
prognosis of those patients with retroperitoneal LN in-
volvement only might be the higher optimal
Fig. 1 Disease-free survival curve of the retroperitoneal-only disease (RP) group (n= 35) compared to those of intraperitoneal only disease (IP) group (n= 72)
and combination of intraperitoneal and retroperitoneal disease (IP/RP) group (n= 72) in women with non-serous epithelial ovarian cancer (n= 179)
Fig. 2 Overall survival curve of the retroperitoneal-only disease (RP) group (n = 35) compared to those of intraperitoneal only disease (IP) group (n= 72)
and combination of intraperitoneal and retroperitoneal disease (IP/RP) group (n = 72) in women with non-serous epithelial ovarian cancer (n = 179)
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cytoreduction rate compared to the patients with intra-
peritoneal tumor implants > 2 cm [10]. However, given
the significant differences in DFS and OS detected in
our study among different patient groups according to
the route of spread, we suggest that biology of the
tumor rather than maximal surgical effort is associated
with survival differences in these subgroups of patients
as all patients included in the current study underwent
optimal cytoreduction.
In a study of 107 patients with HGSC, Bakker et al. [8]
reported that patients with pelvic and/or paraaortic LN
metastases without extrapelvic peritoneal involvement
(n = 13) had statistically significant better OS compared
with other patients (n = 94) who had extrapelvic periton-
eal involvement with or without nodal metastases. Our
study confirmed these results in a homogenous popula-
tion of non-serous EOC patients. However, Bakker et al.
suggested that regional LN metastasis in ovarian serous
carcinoma patients may be a poor prognostic indicator
only in the presence of extra pelvic peritoneal metastasis
Table 2 Univariate and multivariate analyses for disease-free
survival in women with ovarian non-serous carcinoma
DFSa Eventsb Univariate Multivariate
p HR CI 95% p
Age, y
≤ 53 51.9% 44/87
(50.6%)
> 53 26.7% 61/92
(66.3%)
0.025
Menopausal Status
Premenopausal
56.1% 32/70
(45.7%)
0.003
Postmenopausal
27.7% 73/109
(66.9%)
Histologic type
Clear 29.3% 31/48
(64.6%)
0.310
Müsinöz 48.3% 27/47
(53.8%)
Endometrioid 41.8% 28/52
(53.8%)
Mixt 33.6% 19/32
(59.3%)
Route of Spread
Intraperitoneal
37.6% 43/72
(59.7%)
0.002
Retroperitoneal
66.4% 14/35
(40%)
Intra
+Retroperitoneal
25.5% 48/72
(66.6%)
Peritoneal cytology
Positive 38.1% 37/61
(60.6%)
0.717
Negative 40.8% 68/118
(57.6%)
Bilateralty
Unilateral 49.4% 49/97
(50.5%)
0.010
Bilateral 26.8% 56/82
(68.2%)
Tumor size(cm)
< 10 53.4% 21/45
(46.6%)
0.321
≥ 10 63.3% 16/48
(33.3%)
CA-125(IU/ml)
< 250 38.4% 55/88
(31.4%)
0.720
≥ 250 39% 47/84
(44.8%)
Ascites
Yes 40.6% 0.131
Table 2 Univariate and multivariate analyses for disease-free
survival in women with ovarian non-serous carcinoma
(Continued)
DFSa Eventsb Univariate Multivariate
p HR CI 95% p
41/79
(51.9%)
No 39% 64/100
(64%)
LN involvement
Yes 39.9% 62/107
(57.9%)
0.761
No 37.6% 43/72
(59.7%)
Omental involvement
Yes 26.7% 73/106
(68.8%)
< 0.001
No 57.5% 31/71
(43.6%)
Grade
Grade 1-2 63% 26/64
(40.6%)
< 0.001 2.3 1.421-
3.929
0.001
Grade 3 24.4% 48/67
(71.6%)
CRS
Maximal 83.1% 9/51
(17.6%)
< 0.001 5.3 2.374-
12.142
< 0.001
Optimal 23.3% 96/128
(75%)
Characters in bold indicate statistical significance
Abbreviations: DFS disease free survival, LN lymph node, CRS
cytoreductive surgery
a5-year recurrence free survival rate
bThe number of cases with recurrence or death whichever occurred first
Sahin et al. Journal of Ovarian Research  (2018) 11:21 Page 7 of 10
[8]. We were not able to confirm this finding in our co-
hort as we were unable to demonstrate a significant dif-
ference in terms of DFS and OS when the IP group was
compared to the IP/RP group.
We demonstrated a significant improvement in DFS
and OS for node-positive-only disease compared to IP
only tumor or a combination of IP and RP disease in a
cohort of 179 women with non-serous EOC. Our re-
sults are comparable to those of Rungruang et al. [9]
who included 203 patients with exclusively LN involve-
ment. This is the largest study reported to date in terms
of number of patients having node-positive-only disease
[9]. However, it seems interesting that the number of
patients with IP disease (n = 123) was less than the
number of patients with only RP disease (n = 203) in
the Rungruang study [9]; a finding not compatible with
previous studies in the literature [3–8, 10]. It should be
emphasized that non-serous histology constituted
30.5% of their study population. Table 4 demonstrates
the number of patients according to the histotype in
previous studies associated with node-positive- only
disease in epithelial ovarian cancer.
Table 3 Univariate and multivariate analyses for overall survival
in women with ovarian non-serous carcinoma
OSa Eventsb Univariate Multivariate
p HR CI 95% p
Age, y
≤53 61.5% 29/87
(33.3%)
0.004
> 53 40.9% 51/92
(55.4%)
Menopausal Status
Premenopausal
66.4% 21/70
(30%)
0.001
Postmenopausal
40.8% 59/109
(54.1%)
Histologic type
Clear 40.4% 26/48
(54.1%)
0.335
Müsinöz 55.8% 23/47
(48.9%)
Endometrioid 51.7% 21/52
(40.4%)
Mixt 59.9% 10/32
(31.2%)
Route of Spread
Intraperitoneal 54% 31/72
(43%)
0.011
Retroperitoneal
74.4% 10/35
(28.6%)
Intra
+Retroperitoneal
36% 39/72
(54.1%)
Peritoneal cytology
Positive 50.5% 51/118
(43.2%)
0.987
Negative 51.1% 29/61
(47.5%)
Bilateralty
Unilateral 59.7% 40/97
(41.2%)
0.293
Bilateral 40.2% 40/82
(48.7%)
Tumor size(cm)
< 10 47.7% 38/78
(48.7%)
0.169
≥ 10 53.5% 42/101
(41.6%)
CA-125(IU/ml)
< 250 56.2% 39/88
(44.3%)
0.690
≥ 250 44.5% 39/84
(46.4%)
Ascites
Yes 45.4% 0.150
Table 3 Univariate and multivariate analyses for overall survival
in women with ovarian non-serous carcinoma (Continued)
OSa Eventsb Univariate Multivariate
p HR CI 95% p
50/100
(50%)
No 58.1% 30/79
(37.9%)
LN involvement
Yes 49% 49/107
(45.8%)
0.955
No 54% 31/72
(43%)
Omental involvement
Yes 38.9% 57/106
(53.7%)
0.001
No 66.8% 22/71
(30.9%)
Grade
G1-2 69% 19/69
(27.5%)
0.003 1.9 1.071-
3.421
0.028
G3 42% 35/67
(52.2%)
CRS
Maximal 94.5% 4/51
(7.8%)
< 0.001 5.5 1.968-
15.625
0.001
Optimal 36.2% 76/128
(59.3%)
Characters in bold indicate statistical significance
Abbreviations: OS overall survival, LN lymph node, CRS cytoreductive surgery
a5-year overall survival
bThe number of cases with death
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Precise histopathologic diagnosis is mandatory for suc-
cessful categorization and treatment of EOCs, as differ-
ent histologic types respond differently to treatment
[20]. We considered that it is crucial to investigate the
prognosis of patients according to the pattern of spread
with specific regard to histological subtypes in order to
evaluate the outcome in individual subgroups in a multi-
center analysis. However, the small number of patients
in each histotype group did not allow us to perform sub-
group analyses of patients with specific regard to the his-
totypes such as endometrioid, clear-cell, mucinous and
mixed.
The strengths of the current study lie in its multicen-
ter nature with a large number of patients with non-
serous EOC. Our study has the advantage that its time
period encompasses the last 10 years, during which all
patients were treated with carboplatin plus paclitaxel
with a uniformity of applying the same adjuvant treat-
ment. Additionally, all of the patients in the current
study underwent LND.
Conclusions
We conclude that primary non-serous EOC patients
with node-positive-only disease have better survival than
those with extra-pelvic peritoneal involvement. Further
studies with larger number of patients in each histologic
subtype group are needed in order to demonstrate this
survival benefit with specific regard to rare non-serous
histotypes such as endometrioid, clear-cell, and mucin-
ous carcinoma of the ovary.
Abbreviations
CA 125: Cancer antigen 125; DFS: Disease-free survival; EOC: Epithelial ovarian
cancer EOC; FIGO: International Federation of Gynecology and Obstetrics;
HGSC: High-grade serous carcinoma; IP: Intraperitoneal; LGSC: Low-grade
serous carcinoma; LN: Lymph node; OS: Overall survival; RD: Residual disease;
RP: Retroperitoneal; WHO: World Health Organization
Acknowledgements
Not applicable.
Funding
Not applicable.
Availability of data and materials
The dataset used and analyzed during the current study is available from the
corresponding author on reasonable request.
Authors’ contributions
Conceptualization: HS, MMM, AA. Methodology: HS, MMM, MES, AA.
Software: MES, GC, NTO, KG, OA, MD, MCS, BE. Validation: HS, MMM, MES, AA.
Formal Analysis: HS, MMM, MES. Investigation: HS, MES, GC, NTO, ZFC, KG, BE,
IY. Resources: MMM, GC, KG, OA, MD, MCS, TG, AA. Data Curation: MES, GC,
NTO, ZFC, KG, BE, IY. Writing original draft: HS, MMM. Writing-review & edit-
ing: HS, MMM, MES, GC, NTO, ZFC, KG, OA, MD, MCS, BE, İY, TG, AA.
Visualization: HS, MES, GC, NTO, ZFC, KG, BE, IY. Supervision: MMM, OA, MD,
MCS, TG, AA. Project Administration: MMM. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
The study protocol was approved by the Local Institutional Review Board
(Zekai Tahir Burak Women’s Health Training and Research Hospital, Faculty of
Medicine, University of Health Sciences, Ankara, Turkey, IRB Approval
Number:10, Date: Nov 2nd, 2016). All patients provided an informed consent
regarding research use of their medical information at admission.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Gynecologic Oncology, Zekai Tahir Burak Women’s Health
Training and Research Hospital, Faculty of Medicine, University of Health
Sciences, Ankara, Turkey. 2Division of Gynecologic Oncology, Department of
Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Adana,
Turkey. 3Department of Gynecologic Oncology, Kanuni Sultan Suleyman
Teaching and Research Hospital, Faculty of Medicine, University of Health
Sciences, Istanbul, Turkey. 4Department of Gynecologic Oncology, Tepecik
Education and Research Hospital, Faculty of Medicine, University of Health
Sciences, Izmir, Turkey. 5Department of Obstetrics and Gynecology, Gulhane
Table 4 The number of patients according to the histotype in previous studies associated with node-positive- only disease in
epithelial ovarian cancer
Author Patients
(n)
NP-ODa
(n)
Serous
(n)
Endometrioid
(n)
Clear-cell
(n)
Mucinous
(n)
Mixed
(n)
Others
(n)
Onda, 1998 [3] 103 14 48 9 22 17 2 5
Kanazawa, 1999 [4] 125 35 54 13 13 25 – 6
Cliby, 2006 [5] NR 36 NR NR NR NR NR NR
Ferrandina, 2007 [6] 118 26 NR NR NR NR NR NR
Baek, 2008 [7] 272 41 197 23 4 13 23 12
Rungruang, 2012 [9] 417 203 290 37 34 9 29 18
Bakkar, 2014 [8] 107 13 107 – – – – –
Suh, 2014 [10] 483 33 NR NR NR NR NR NR
Present study 179 35 – 52 48 47 32 –
Abbreviation: NR not reported
aNumber of patients with node positive-only disease
Sahin et al. Journal of Ovarian Research  (2018) 11:21 Page 9 of 10
Training and Researh Hospital, Faculty of Medicine, University of Health
Sciences, Ankara, Turkey. 6Division of Gynecologic Oncology, Department of
Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University,
Ankara, Turkey.
Received: 31 December 2017 Accepted: 26 February 2018
References
1. Berek JS. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
Int J Gynecol Cancer. 2009;19 Suppl 2:S18–20.
2. Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S, Velipasaoglu
M, Yuce K. Metastatic lymph node number in epithelial ovarian carcinoma:
does it have any clinical significance? Gynecol Oncol. 2008;108:428–32.
3. Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M,
Matsumoto K, Taketani Y. Patients with ovarian carcinoma upstaged to stage III
after systematic lymphadenctomy have similar survival to stage I/II patients
and superior survival to other stage III patients. Cancer. 1998;83:1555–60.
4. Kanazawa K, Suzuki T, Tokashiki M. The validity and significance of substage
IIIC by node involvement in epithelial ovarian cancer: impact of nodal
metastasis on patient survival. Gynecol Oncol. 1999;73:237–41.
5. Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients
to stage IIIC epithelial ovarian cancer based on nodal involvement only?
Gynecol Oncol. 2006;103:797–801.
6. Ferrandina G, Scambia G, Legge F, Petrillo M, Salutari V. Ovarian cancer
patients with “node-positive-only” stage IIIC disease have a more favorable
outcome than stage IIIA/B. Gynecol Oncol. 2007;107:154–6.
7. Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Stage IIIC epithelial
ovarian cancer classified solely by lymph node metastasis has a more favorable
prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol
Oncol. 2008;19:223–8.
8. Bakkar R, Gershenson D, Fox P, Vu K, Zenali M, Silva E. Stage IIIC ovarian/
peritoneal serous carcinoma: a heterogeneous group of patients with
different prognoses. Int J Gynecol Pathol. 2014;33:302–8.
9. Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA,
Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be
further stratified by intraperitoneal vs. retroperitoneal only disease?: a
gynecologic oncology group study. Gynecol Oncol. 2012;124:53–8.
10. Suh DH, Kim TH, Kim JW, Kim SY, Kim HS, Lee TS, Chung HH, Kim YB, Park
NH, Song YS. Improvements to the FIGO staging for ovarian cancer:
reconsideration of lymphatic spread and intraoperative tumor rupture. J
Gynecol Oncol. 2013;24:352–8.
11. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic
alterations, and clinicopathological features. Virchows Arch. 2012;460:237–49.
12. Kurman RJ, Carcangui ML, Herrington CS, Young RH. Tumors of the ovary,
WHO classification of tumours of female reproductive organs. 4th ed. Lyon:
IARC; 2014. p. 11–4.
13. Di Re F, Fontanelli R, Raspagliesi F, Di Re E. Pelvic and Para-aortic lymphadenectomy
in cancer of the ovary. Baillieres Clin Obstet Gynaecol. 1989;3:131–42.
14. Petru E, Lahousen M, Tamussino K, Pickel H, Stranzl H, Stettner H, Winter R.
Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;
170:656–62.
15. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M,
Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary:
a distinct histologic type with poor prognosis and resistance to platinum-
based chemotherapy. Cancer. 2000;88:2584–9.
16. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ,
Park RC. Long-term follow-up and prognostic factor analysis in advanced
ovarian carcinoma: the gynecologic oncology group experience. J Clin
Oncol. 1991;9:1138–50.
17. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos
G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian
cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;
11:719–25.
18. Prat J, Oncology FCoG. Staging classification for cancer of the ovary,
fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
19. Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph
node metastasis in apparent early-stage epithelial ovarian cancer:
implications for surgical staging. Gynecol Oncol. 2011;122:536–40.
20. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and
peritoneal cancer. Gynecol Oncol. 2014;133:401–4.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sahin et al. Journal of Ovarian Research  (2018) 11:21 Page 10 of 10
